Lead Product(s): Propranolol
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Atnahs Pharma
Deal Size: $390 million Upfront Cash: $350 million
Deal Type: Divestment January 27, 2020
AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.